NASDAQ:SNOA

Sonoma Pharmaceuticals Q1 2026 Earnings Results & Report

Sonoma Pharmaceuticals logo
$0.72 -0.09 (-10.83%)
Closing price 04:00 PM Eastern
Extended Trading
$0.72 -0.01 (-0.69%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sonoma Pharmaceuticals beat analyst earnings expectations but missed on revenue in its Q1 2026 results, released August 7, 2025. The company reported EPS of -$0.37 versus the -$0.51 consensus estimate, while revenue of $4.01 million fell short of the $4.26 million estimate by $250 thousand.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens

Sonoma Pharmaceuticals EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.51
Beat/Miss
Beat by +$0.14
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Sonoma Pharmaceuticals Revenue Results

Actual Revenue
$4.01 million
Expected Revenue
$4.26 million
Beat/Miss
Missed by -$250.00 thousand
YoY Revenue Growth
N/A

Conference Call Resources

Sonoma Pharmaceuticals Q1 2026 Earnings FAQ

Sonoma Pharmaceuticals (NASDAQ:SNOA) reported earnings of -$0.37 per share for Q1 2026, beating the consensus estimate of -$0.51. The report was announced on Thursday, August 7, 2025.

Sonoma Pharmaceuticals reported revenue of $4.01 million for Q1 2026, against a consensus estimate of $4.26 million.

Sonoma Pharmaceuticals Earnings Headlines

6 Men Secretly Changed America’s Money. Now It’s Happening Again
In 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's financial system for generations. Now six financial giants controlling $24 trillion have aligned behind a new initiative that Grey Swan Investment Fraternity's Andrew Packer says could echo that moment in history. Addison Wiggin outlines three steps investors might consider before November 30th, including one stock ticker being shared at no cost.tc pixel
See More Sonoma Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sonoma Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sonoma Pharmaceuticals and other key companies, straight to your email.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals (NASDAQ:SNOA) develops and markets products based on its stabilized hypochlorous acid technology for human and animal health. Its product portfolio includes solutions and gels for wound care, skin conditions, eye care and other hygiene applications.

The company’s offerings include Microcyn-branded products, which are used in areas such as wound management and dermatology, as well as products for veterinary care. Sonoma sells its products through commercial partners and distributors in the United States and international markets.

The company was formerly known as Oculus Innovative Sciences and adopted the Sonoma Pharmaceuticals name in 2016. Its business has since focused on developing and commercializing hypochlorous acid-based products for healthcare and related markets.

View Sonoma Pharmaceuticals Profile